COMPANY
Vogenx
Funding and NIH signals
- SEC Form D raise Raised $750K in debt securities (Form D filed Jan 7, 2026). SEC Form D 0001903784-26-000002 (Jan 7, 2026)
Evidence (1 event)
- Jan 7, 2026 · SEC Form D 0001903784-26-000002
Name of Issuer: Vogenx, Inc.; CIK: 1903784; Address: Raleigh, NC; Submission type: D; Filing date: 2026-01-07; Industry Group: Pharmaceuticals; Date of First Sale: 2025-12-10; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 750000; Federal exemptions: 06b
- Jan 7, 2026 · SEC Form D 0001903784-26-000002
Timeline
- Trial start Phase 2: Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia source ↗
- Trial start Phase 2: Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions source ↗
- Trial start Phase 2: Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects source ↗
Upcoming milestones
- 2027-10 (ESTIMATED) · Phase 2 · Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia · NCT07760961
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07760961 | Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia | Phase 2 | Not yet recruiting | 2026-10 | 2027-10 (estimated) |
| NCT05721729 | Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions | Phase 2 | Completed | Jun 23, 2023 | May 1, 2024 (actual) |
| NCT05541939 | Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects | Phase 2 | Completed | Sep 13, 2022 | Feb 17, 2023 (actual) |
Raises and investors new
- Raise Private raise (SEC Form D): $750K sold of $5.0M offered; issuer “Vogenx, Inc.”. Verified from the SEC filing. SEC filing ↗